Table 1 Characteristics of study participants: age at diagnosis and age at the study, follow-up time and tumour characteristics.
Total | I131 treatment | Controls | p | |
|---|---|---|---|---|
No. patients | 51 | 40 | 11 | |
Initial agea | ||||
Years (mean ± SD) | 30.8 ± 8.3 | 29.6 ± 8.2 | 35.2 ± 7.9 | 0.048 |
Range | 15.4–44.9 | 15.4–44.9 | 22.1–44.4 | |
Final ageb | ||||
Years (mean ± SD) | 43.5 ± 9.2 | 39.7 ± 6.8 | 42.7 ± 5.5 | 0.856 |
Range | 24.3–65.3 | 24.3–65.3 | 29.7–55.6 | |
Follow up period | ||||
Years (mean ± SD) | 12.6 ± 9.8 | 13.7 ± 9.7 | 8.7 ± 9.7 | 0.135 |
Median | 12.5 | 14.3 | 4.3 | |
Range | 0.5–36.8 | 0.6–36.8 | 0.5–25.6 | |
Microcarcinoma (< 1 cm)c | 12/47 (25.5%) | 4/36 (11.1%) | 8/11 (72.7%) | 0 |
Low Risk (ATA)d | 34/51 (66.7%) | 23/40 (57.5%) | 11/11 (100.0%) | 0.009 |
BRAF+ | 11/20 (55.0%) | 10/18 (55.6%) | 1/2 (50.0%) | – |
KRAS+ | 1/3 (33.3%) | 1/3 (33.3%) | 0/0 (0.0%) | – |
